Physician profile
Daljeet Singh
NPI 1598784092
$871.21
in general payments reported to CMS, 2019-2025
17 companies · $16.55 in 2025
The $16.55 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $49.74 · 2021: $11.92 · 2022: $335 · 2023: $269 · 2025: $16.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $183.83 | 2022-2023 | |
| Eisai INC. | $142.66 | 2019 | |
| Genentech USA, INC. | $114.29 | 2022-2023 | Venclexta, Lunsumio, Phesgo |
| Pharmacyclics LLC, An Abbvie Company | $61.03 | 2023 | Epkinly, Imbruvica |
| Gilead Sciences, INC. | $58.85 | 2021-2023 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $53.75 | 2022-2025 | |
| Amgen INC. | $49.94 | 2019-2023 | Kyprolis |
| Merck Sharp & Dohme LLC | $40.92 | 2019-2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $30.30 | 2023 | Opdivo |
| Aveo Pharmaceuticals, INC. | $25.51 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.07 | 2020 | |
| Celgene Corporation | $18.34 | 2022 | |
| Portola Pharmaceuticals, LLC | $15.53 | 2019 | |
| Stemline Therapeutics INC. | $13.98 | 2023 | Orserdu |
| Janssen Biotech, INC. | $13.32 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.54 | 2022 | |
| Karyopharm Therapeutics INC. | $11.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daljeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.